Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

- Company on Target to File NDA in Second Quarter of 2008 -

CORONA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced positive results today from its Phase 3 study of oxybutynin topical gel (OTG) in patients with overactive bladder (OAB). The study met its primary endpoint of a statistically significant reduction in incontinence episodes, and secondary endpoints of reduction in frequency and increases in void volume compared with placebo, while demonstrating a low incidence of side effects.

"We are extremely encouraged with the results from this trial which will support our NDA submission, and we are on track to file with FDA in the second quarter of 2008," said Paul Bisaro, Watson's President and Chief Executive Officer. "Additionally, we have the potential to introduce the first gel formulation for the treatment of overactive bladder in 2009."

"Offering patients the ease and comfort of a daily gel for the treatment of OAB may provide greater patient acceptability and persistence on treatment," said Peter K. Sand, M.D., director of the Evanston Continence Center, Evanston Northwestern Healthcare, Northwestern University, Feinberg School of Medicine and Professor of Obstetrics and Gynecology and Director of the Division of Urogynecology, Evanston, IL.

It is well recognized that transdermal delivery of oxybutynin is a safe and effective treatment for OAB. By delivering oxybutynin transdermally, first-pass gastric and hepatic metabolism is bypassed, which is believed to result in lower anticholinergic side effects such as dry mouth and constipation. These side effects result in a significant level of patient non-compliance a
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Landscape Poland " an essential source of information ... market and provides insights into the demographic, regulatory, ... report provides valuable insights into the trends and ...
(Date:8/28/2014)... Aug. 28, 2014 Tianyin Pharmaceutical Co., ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today updates the timeline for ... (QLF). The Company is scheduled ... for China Food & Drug Administration,s (CFDA) review ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training ... published a case study highlighting one manager,s ... . In September and October 2014, Academy Leadership affiliates ... Albuquerque , Indianapolis , Salt Lake City ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... During Wednesday,s Satellite Symposium,3: The Challenges of ... the,International Society of Heart and Lung Transplantation ... researchers discussed some of,the unique challenges in ... CF., A highlight of the session ...
... to be Presented at the Upcoming ECCMID Conference, ... the,press release published on 9 April, Arpida Ltd. ... the clinical programme with,intravenous iclaprim in complicated Skin ... has been presented at last year,s ICAAC,and IDSA ...
Cached Medicine Technology:Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 2Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 3Arpida Provides Further Comments on the Pivotal Phase III Trials 2Arpida Provides Further Comments on the Pivotal Phase III Trials 3Arpida Provides Further Comments on the Pivotal Phase III Trials 4
(Date:8/28/2014)... (PRWEB) August 28, 2014 American adults ... industry on the Internet will now have a simpler ... company. In one click this year, some of the ... http://quotespros.com/life-insurance.html . , The promoted plans that ... Pros finder tool represent popular policies. The term, guaranteed ...
(Date:8/28/2014)... NH As the federal government plans its exit strategy ... to rethink its role in providing health care to veterans, ... of Medicine . , "To simply go on doing more ... that the Veterans Health Administration,s cost and population structure pose ... Institute for Health Policy & Clinical Practice, and David Auerbach, ...
(Date:8/28/2014)... and Ann Arbor, MI (PRWEB) August 28, 2014 ... company and the nation’s leading intraoperative neurophysiology monitoring ("IONM") ... and CFO, to the position of Chief Executive Officer ... CFO, was promoted to President and CFO in 2013 ... growth and success. , “Bill’s efforts and achievements ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , ... record by walking 5,000 miles in a single year without ... the thousands of individual stories of TrekDesk treadmill desk users ... more than the others. , Kirklyn has launched a website ... a range of 54,823 steps (presumably on an off day) ...
(Date:8/28/2014)... San Mateo, CA (PRWEB) August 28, 2014 ... announce that the MRI Technology program is re-accredited for ... Registry of Magnetic Resonance Imaging Technologists (ARMRIT). , ... re-accreditation. We are constantly improving our program to make ... There is a lot of interest in MRI field ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:A VA exit strategy 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... Medical,Equipment, Inc. (Pink Sheets: SHMM) announced today that ... completed its seventh,staffing agreement and is aggressively filling ... CEO of parent company Southern Home Medical,stated, "This ... has far,exceeded their own expectations in their second ...
... June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced ... candidate in its Beta-catenin Pathway Inhibitor program. This novel compound ... cancer cell death. The Company plans to begin ... is one of the most commonly activated cancer pathways and ...
... Pryor, CEO of Portico,Learning Solutions (Portico), a provider ... Portico,s partnership with FOX,Networks Group (FNG), the umbrella ... Networks, FOX Reality, and the National Geographic,Channel., ... News Corporation businesses,FNG launched a massive effort to ...
... Mandate is Quick to Implement, ROCKLIN, Calif., ... a provider of relay and wireless communications and,professional ... AT&T today announced they would become the,first companies ... a,10-digit numbering system described in the FCC ruling ...
... The International Association for Dental Research (IADR) is presenting ... Lecturer in Periodontology at the School of Dental Sciences ... will be presented at the IADR 86th General Session ... Dr. Preshaw holds a B.D.S. from Newcastle University, a ...
... Va. The International Association for Dental Research ... Diagnostic Sciences (Emeritus) at the School of Dental ... Buffalo, as the 2008,recipient of the Pharmacology/Therapeutics/Toxicology Research ... IADR 86th,General Session & Exhibition in Toronto, ON, ...
Cached Medicine News:Health News:Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement 2Health News:Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program 2Health News:FOX Networks Group in Partnership with Portico Learning Solutions Launches Online Employee Health and Safety Orientation Course for Over 3,300 Employees 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 3Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 4Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 5Health News:Fischman receives Pharmacology/Therapeutics/Toxicology Research Award 2
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Nebulizer Adapter Kit 6"...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
Medicine Products: